Real-life evaluation of novel forced expiratory ratios with asthma exacerbations and symptoms

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001399" target="_blank" >RIV/00064190:_____/25:10001399 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10506377

Výsledek na webu

<a href="https://doi.org/10.1016/j.anai.2025.08.015" target="_blank" >https://doi.org/10.1016/j.anai.2025.08.015</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.anai.2025.08.015" target="_blank" >10.1016/j.anai.2025.08.015</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-life evaluation of novel forced expiratory ratios with asthma exacerbations and symptoms

Popis výsledku v původním jazyce

Background Small airway dysfunction is an important treatable trait in persistent asthma but remains poorly captured by conventional spirometry. The (forced expiratory volume in 3 seconds [FEV3]-FEV1)/forced vital capacity (FVC) and FEV3/FEV6 ratios have been proposed as novel markers of peripheral airflow limitation. Objective To investigate the relationship between (FEV3-FEV1)/FVC and FEV3/FEV6 with symptom control and the frequency of severe exacerbations in patients with moderate-to-severe asthma. Methods Clinical, physiological, and biomarker data were collected from adults with Global Initiative for Asthma-defined moderate-to-severe asthma visiting a specialist severe asthma center in Scotland, United Kingdom. Associations between spirometric and oscillometric parameters with clinically relevant outcomes were retrospectively analyzed using multivariate models. Results A total of 294 patients were included in the analysis. The (FEV3-FEV1)/FVC and FEV3/FEV6 ratios were not significantly associated with asthma symptoms or severe exacerbation rates. Conversely, traditional measures such as FEV1/FVC (adjusted odds ratio [95% CI], 2.11 [1.27-3.50]; P &lt; .01), forced expiratory flow rate between 25% and 75% of the FVC/FVC (2.11 [1.27-3.50]; P &lt; .01), and oscillometric Rrs(5-20) (1.90 [1.14-3.16]; P &lt; .05) were significantly associated with more than or equal to 2 exacerbations in the previous year. High coefficient of determination (r(2)) values were observed between FEV1/FVC with (1) (FEV3-FEV1)/FVC (r(2) = 0.61) and (2) FEV3/FEV6 (r(2) = 0.83), suggesting overlapping aspects of lung function being measured. There was a weak correlation between FEV1/FVC and Rrs(5-20) values (r(2) = 0.08) indicating that these parameters assess unique aspects of lung function and mechanics. Conclusion In moderate-to-severe asthma, the (FEV3-FEV1)/FVC and FEV3/FEV6 ratios were not independently associated with exacerbation risk or symptom control and did not provide additional clinical value compared with conventional lung function measures (c) 2025 American College of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Název v anglickém jazyce

Real-life evaluation of novel forced expiratory ratios with asthma exacerbations and symptoms

Popis výsledku anglicky

Background Small airway dysfunction is an important treatable trait in persistent asthma but remains poorly captured by conventional spirometry. The (forced expiratory volume in 3 seconds [FEV3]-FEV1)/forced vital capacity (FVC) and FEV3/FEV6 ratios have been proposed as novel markers of peripheral airflow limitation. Objective To investigate the relationship between (FEV3-FEV1)/FVC and FEV3/FEV6 with symptom control and the frequency of severe exacerbations in patients with moderate-to-severe asthma. Methods Clinical, physiological, and biomarker data were collected from adults with Global Initiative for Asthma-defined moderate-to-severe asthma visiting a specialist severe asthma center in Scotland, United Kingdom. Associations between spirometric and oscillometric parameters with clinically relevant outcomes were retrospectively analyzed using multivariate models. Results A total of 294 patients were included in the analysis. The (FEV3-FEV1)/FVC and FEV3/FEV6 ratios were not significantly associated with asthma symptoms or severe exacerbation rates. Conversely, traditional measures such as FEV1/FVC (adjusted odds ratio [95% CI], 2.11 [1.27-3.50]; P &lt; .01), forced expiratory flow rate between 25% and 75% of the FVC/FVC (2.11 [1.27-3.50]; P &lt; .01), and oscillometric Rrs(5-20) (1.90 [1.14-3.16]; P &lt; .05) were significantly associated with more than or equal to 2 exacerbations in the previous year. High coefficient of determination (r(2)) values were observed between FEV1/FVC with (1) (FEV3-FEV1)/FVC (r(2) = 0.61) and (2) FEV3/FEV6 (r(2) = 0.83), suggesting overlapping aspects of lung function being measured. There was a weak correlation between FEV1/FVC and Rrs(5-20) values (r(2) = 0.08) indicating that these parameters assess unique aspects of lung function and mechanics. Conclusion In moderate-to-severe asthma, the (FEV3-FEV1)/FVC and FEV3/FEV6 ratios were not independently associated with exacerbation risk or symptom control and did not provide additional clinical value compared with conventional lung function measures (c) 2025 American College of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30225 - Allergy

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ANNALS OF ALLERGY ASTHMA &amp; IMMUNOLOGY

ISSN

1081-1206

e-ISSN

1534-4436

Svazek periodika

135

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

nestránkováno

Kód UT WoS článku

001630611500012

EID výsledku v databázi Scopus

2-s2.0-105022130896